Menu
Search
|

Menu

Close
X

Xenon Pharmaceuticals Inc XENE.OQ (NASDAQ Stock Exchange Global Market)

3.75 USD
+0.05 (+1.35%)
As of 8:59 PM GMT
chart
Previous Close 3.70
Open 3.75
Volume 7,460
3m Avg Volume 11,445
Today’s High 3.75
Today’s Low 3.65
52 Week High 9.90
52 Week Low 2.15
Shares Outstanding (mil) 18.00
Market Capitalization (mil) 54.00
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.33 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
2
FY15
16
EPS (USD)
FY17
-1.259
FY16
-1.485
FY15
-1.109
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
65.85
5.77
Price to Book (MRQ)
vs sector
1.07
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-55.45
14.43
Return on Equity (TTM)
vs sector
-55.50
16.13

EXECUTIVE LEADERSHIP

Michael Tarnow
Chairman of the Board, Since
Salary: --
Bonus: --
Ian Mortimer
Chief Financial Officer, Chief Operating Officer, Since 2015
Salary: $281,763.00
Bonus: --
James Empfield
Senior Vice President - Drug Discovery, Since 2016
Salary: --
Bonus: --
Robin Sherrington
Senior Vice President of Business and Corporate Development, Since 2012
Salary: $231,313.00
Bonus: --
Charles Cohen
Vice President - Biology, Since 2008
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3650 Gilmore Way
BURNABY   BC   V5G 4W8

Phone: +1604.4843300

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.

SPONSORED STORIES